Cost-Effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States.
Ontology highlight
ABSTRACT: To inform proposed changes in U.S. HCV screening guidelines, we assessed the cost-effectiveness of HCV antenatal rescreening for women without evidence of HCV during a prior pregnancy, using a previously published model. Universal HCV rescreening among pregnant women was cost-effective (ICER $6,000/QALY) and should be recommended nationally.
SUBMITTER: Chaillon A
PROVIDER: S-EPMC8563211 | biostudies-literature |
REPOSITORIES: biostudies-literature
ACCESS DATA